Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity.
Immune genes may predict who responds to a targeted cancer therapy, opening pathways for better patient selection.
Molecular profiling of tisotumab vedotin (TV)-treated patients identified immune pathway signatures—particularly innate immune and interferon response genes—as predictors of clinical response to this tissue factor-targeting ADC. These findings provide a molecular framework for patient selection and rational combination strategies.
What the study was
- Study design
- translational_biomarker_analysis_of_clinical_cohort
- Category
- precision_oncology
- Maturity
- Validated
Why it surfaced
Precision oncology molecular profiling of an FDA-approved ADC in a clinical cohort published in Clinical Cancer Research. Translational data from trial patients offers biomarker insights for patient selection. Relevant to precision oncology and novel therapeutics watchlists.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.